drugset / Trial / NCT02299245

Rosuvastatin Effect on Telomere-telomerase System in ACS

NCT02299245 ↗

Phase 4 Unknown 400 enrolled Xiao-dong Zhuang Sun Yat-sen University · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Coronary heart disease (CHD) is one of the diseases characterised by biological aging as one of the important risk factors in several epidemiological studies. The mean telomere length and telomerase activity serve as markers for the biological age at the cellular level, with shorter telomeres and lower telomerase activity defining the increased biological age. Telomere length and telomerase activity, therefore, correlates with the risk of CHD and atherosclerosis. A present study states that the treatment with a statin is associated with a reduction in the number of clinical events but only in individuals with increased risk based on their telomere length. This suggests a positive relationship of telomere and telomerase system with the treatment with statins in CHD patients.

Timeline

Start
2014-10
Primary completion
2016-07
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 10 mg —
Subject Rosuvastatin Small molecule 20 mg —